Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
09955 智雲健康
Listing Date2022/07/06
Listing Price30.500
  • 7.880 +0.340 (+4.509%)    Sink Below Listing Price
  • 15-min delayed, last update: 24/03/2023 18:00
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    4 lot
  • One Lot Success Rate

ClouDr Group aspires to lead China’s digital chronic condition management market through solutions serving all major participants in the healthcare value chain, including hospitals, pharmacies, pharmaceutical companies, patients and doctors, including cardiovascular diseases (such as hypertension and hyperlipidemia) and diabetes, among others.

According to the Frost & Sullivan Report, the Group is the largest digital chronic condition management solution provider in China, in terms of numbers of SaaS installations in hospitals and pharmacies in China, each as of December 31, 2021, and number of online prescriptions issued through its services in 2021.

The Group provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients. It mainly generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products. It also generates revenue by providing digital marketing, SaaS and other services.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot100
No. of Offer Shares19.00M shares
No. of International Offer Shares17.10M shares
No. of HK Offer Shares1.90M shares
Offer Price$30.50
Stock Code9955
Sponsor(s)Morgan Stanley Asia Limited, J.P. Morgan Securities (Far East) Limited
Underwriter(s)Morgan Stanley Asia Limited, J.P. Morgan Securities (Asia Pacific) Limited, China International Capital Corporation Hong Kong Securities Limited, CMB International Capital Limited, Valuable Capital Limited
Application PeriodJun 23 (Thu) - noon, Jun 28 (Tue)
Price Determination DateJun 28 (Tue)
Result Announcement DateOn or before Jul 05 (Tue)
Result Announcement DateOn or before Jul 05 (Tue)
Dealings in Shares commence onJul 06, 2022. (Wed)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$30.50
NAV / share ($)$4.65 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 30.5, the net proceeds raised would be HKD 481.70M, of which
60% : Pursue the “hospital-first” strategy and expand hospital network nationwide
25% : Advance medical know-how and technology capabilities to reinforce leadership in the digital healthcare industry
5% : Broaden ecosystem through strategic partnerships, investments and acquisitions in other businesses
10% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.